Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-04-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
2024 年度会计师事务所履职情况评估报告
Regulatory Filings
2025-04-18 Chinese
关于公司2025年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the fiscal year 2025. It includes details about the nature of these transactions, the approval process by the board and audit committee, independent directors' opinions, and the sponsor's verification. The document explicitly states that these transactions do not require shareholder meeting approval and are routine business activities. There are no financial statements or detailed financial performance data presented, only projections and governance-related disclosures about related party transactions. This type of document fits the category of Regulatory Filings (RNS) as it is a regulatory announcement about related party transactions and approvals, not a full financial report or management discussion.
2025-04-18 Chinese
2024年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2024 年度内部控制评价报告' which translates to '2024 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control defects, audit opinions, and corrective actions. The content is focused on internal control evaluation rather than full financial statements or annual performance. It is a standalone report on internal control evaluation, not a full annual report (10-K) or audit report of financial statements. The document length is 4043 characters, which is relatively short but contains substantive evaluation content, not just an announcement. This fits the definition of an Audit Report / Information (AR) as it relates to internal control evaluation and audit opinions on internal controls, excluding full annual reports. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-18 Chinese
2024年度募集资金存放与实际使用情况的专项报告及审核报告
Regulatory Filings
2025-04-18 Chinese
2024年度董事会审计委员会履职情况报告
Regulatory Filings
2025-04-18 Chinese
关于公司2025年度董事、监事和高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2025 remuneration scheme for the company's directors, supervisors, and senior management. It details the salary standards, approval by the board and supervisory committee, and the independent directors' opinion on the remuneration plan. There is no financial performance data or comprehensive report content. The document focuses on compensation information for executives and directors, which fits the definition of Remuneration Information (DEF 14A). The document length is short and it is not a report itself but an announcement of the remuneration scheme.
2025-04-18 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.